DalsnaFinance

Generate Biomedicines $GENB

Health Care

Russell 2000 Massachusetts
Create a scorecard
$13.93
+0.24 (+1.75%)
As of Oct 5, 2026, 3:36 PM EDT
Price history
Loading chart…

Generate Biomedicines (GENB) is trading up at $13.93 (+1.75%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: February 27, 2026 · $16.00 offering · NASDAQ · View IPO details →

Generate Biomedicines revenue & net income history

RevenueNet income
$10.1M−$28.6M−$67.3MQ1 FY2025 revenue: $8.82MQ1 FY2025 net income: −$41.7MQ1 '25Q2 FY2025 revenue: $10.1MQ2 FY2025 net income: −$52.4MQ2 '25Q1 FY2026 revenue: $7.22MQ1 FY2026 net income: −$61.4MQ1 '26Q2 FY2026 revenue: $6.31MQ2 FY2026 net income: −$67.3MQ2 '26
Generate Biomedicines quarterly financial statements
Q1 FY25Mar 2025Q2 FY25Jun 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Income statement
Revenue$8.82M$10.1M$7.22M$6.31M
Growth (year over year)——−18.1%−37.7%
Operating income−$48.2M−$60.1M−$64.1M−$71.6M
Operating margin−546.1%−593.8%−887.5%−1134.2%
Net income−$41.7M−$52.4M−$61.4M−$67.3M
Net margin−472.7%−517.6%−850.6%−1065.2%
EPS (diluted)−$1.62−$1.94−$1.07−$0.52
Balance sheet
Cash and equivalents$220.6M$154.3M$160.6M$135.4M
Total assets——$625.7M$561.7M
Total liabilities——$110.9M$105.6M
Shareholders' equity−$471.0M−$517.8M$514.8M$456.0M
Cash flow
Operating cash flow−$53.2M−$48.8M−$80.4M−$57.9M
Capital expenditure$751.0K$154.0K$3.78M$933.0K
Free cash flow−$53.9M−$48.9M−$84.2M−$58.9M

From Generate Biomedicines's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →

About Generate Biomedicines

Headquarters
Somerville, Massachusetts From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →